Geneos Therapeutics Launches IMPACT31 Trial for Innovative Cancer Immunotherapy

Geneos Therapeutics Launches IMPACT31 Trial for Cancer Immunotherapy

Geneos Therapeutics, a biotherapeutics company focused on personalized cancer treatments, has announced the commencement of the IMPACT31 clinical trial. This Phase 2 randomized trial aims to evaluate the effectiveness of neoantigen-targeted personalized immunotherapy specifically for patients suffering from high-risk hepatocellular carcinoma (HCC), a type of liver cancer, who have undergone curative surgery.

Overview of the IMPACT31 Trial

The IMPACT31 trial will engage approximately 90 high-risk patients across multiple sites globally. This innovative approach, known as personalized immunotherapy (PIC), is designed to equip the patients' immune systems to recognize and attack unique genetic mutations present in their tumor cells, mitigating damage to healthy tissues. The trial will assess the efficacy of Geneos' personalized treatment (GNOS-PV02) against the conventional method of active surveillance that is currently standard in post-operative care for HCC patients.

In a significant development, Dr. Julie Rosenberg has been appointed as Chief Medical Officer at Geneos. Dr. Rosenberg brings extensive experience spanning over two decades in leadership and drug development in the biopharmaceutical field. Her addition is seen as pivotal in steering the IMPACT31 trial and further advancing Geneos' immunotherapy programs.

Exciting Possibilities for Patients

Dr. Niranjan Sardesei, President and CEO of Geneos, expressed enthusiasm about Dr. Rosenberg joining the team, highlighting her invaluable background and connections within the clinical development sector. He emphasized the promising early safety and efficacy results observed in previous trials, indicating the potential for significant progress in treating patients with difficult cancers like HCC and glioblastoma—cancers which have historically shown poor responses to immunotherapy approaches.

Dr. Rosenberg stated, "The clinical data collected so far and the Geneos DNA platform are extraordinarily compelling. This is a crucial period for Geneos, and I am eager to enhance our clinical offerings to provide meaningful breakthroughs for patients fighting hard-to-treat cancers."

Targeting Disease Recurrence

The need for innovative treatment options for HCC patients is paramount. In discussions surrounding the trial design, Dr. Mark Yarchoan from Johns Hopkins University articulated that many patients with HCC experience recurrences even after surgical resection. There are currently no effective therapies to prevent such recurrences, making the IMPACT31 trial a critical step forward.

The trial builds on encouraging preliminary data from a previous Phase 1/2 trial published in 2024, which showcased early efficacy in advanced HCC patients. The approach seeks to apply lessons from successful personalized cancer vaccine developments in various tumor types to lessen recurrence rates and improve patient outcomes.

The Mechanism of Personalized DNA Immunotherapy

Geneos' personalized DNA immunotherapy involves utilizing DNA plasmids capable of encoding up to 40 tumor-specific neoantigens. By sequencing the patient's tumor, the specific neoantigens can be determined and included in an individualized vaccine, which aims to stimulate the immune system to generate CD4 and CD8 T cells, targeting and destroying cancerous cells.

This technique is cancer-agnostic and holds promise for application in a variety of malignancies beyond HCC and glioblastoma.

Conclusion

The initiation of the IMPACT31 trial represents a vital advancement in the quest for effective treatments for high-risk HCC patients. With the potential to transform management practices and improve patient prognoses, the innovative personalized immunotherapy developed by Geneos Therapeutics could pave the way for new standards in oncological care. As the trial progresses, stakeholders in the biopharmaceutical industry and the broader medical community will keenly anticipate the outcomes that emerge from this pioneering research initiative.